PL2916866T3 - Formulacja dwuswoistych przeciwciał mobilizujących limfocyty t (bite) - Google Patents

Formulacja dwuswoistych przeciwciał mobilizujących limfocyty t (bite)

Info

Publication number
PL2916866T3
PL2916866T3 PL13786255T PL13786255T PL2916866T3 PL 2916866 T3 PL2916866 T3 PL 2916866T3 PL 13786255 T PL13786255 T PL 13786255T PL 13786255 T PL13786255 T PL 13786255T PL 2916866 T3 PL2916866 T3 PL 2916866T3
Authority
PL
Poland
Prior art keywords
bites
bispecific
formulation
cell engagers
engagers
Prior art date
Application number
PL13786255T
Other languages
English (en)
Inventor
Carsten Olbrich
Thomas Bunte
Jonas WINTER
Jörg Peters
Thomas Trill
Original Assignee
Bayer Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft
Publication of PL2916866T3 publication Critical patent/PL2916866T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL13786255T 2012-11-06 2013-11-05 Formulacja dwuswoistych przeciwciał mobilizujących limfocyty t (bite) PL2916866T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12191493 2012-11-06
EP13786255.3A EP2916866B1 (de) 2012-11-06 2013-11-05 Formulierung für bispecific t-cell-engangers (bites)
PCT/EP2013/073024 WO2014072277A1 (de) 2012-11-06 2013-11-05 Formulierung für bispecific t-cell-engangers (bites)

Publications (1)

Publication Number Publication Date
PL2916866T3 true PL2916866T3 (pl) 2018-10-31

Family

ID=47143702

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13786255T PL2916866T3 (pl) 2012-11-06 2013-11-05 Formulacja dwuswoistych przeciwciał mobilizujących limfocyty t (bite)

Country Status (27)

Country Link
US (1) US11052128B2 (pl)
EP (1) EP2916866B1 (pl)
JP (1) JP6321667B2 (pl)
KR (1) KR20150082328A (pl)
CN (1) CN104780940B (pl)
AR (1) AR093365A1 (pl)
AU (2) AU2013343638B2 (pl)
CA (1) CA2890166C (pl)
CY (1) CY1120391T1 (pl)
DK (1) DK2916866T3 (pl)
ES (1) ES2676468T3 (pl)
HR (1) HRP20181021T1 (pl)
HU (1) HUE038151T2 (pl)
IL (1) IL238615A0 (pl)
LT (1) LT2916866T (pl)
MX (1) MX367034B (pl)
NZ (1) NZ707895A (pl)
PL (1) PL2916866T3 (pl)
PT (1) PT2916866T (pl)
RS (1) RS57394B1 (pl)
RU (1) RU2679124C2 (pl)
SG (1) SG11201502730SA (pl)
SI (1) SI2916866T1 (pl)
SM (1) SMT201800335T1 (pl)
TR (1) TR201809507T4 (pl)
TW (1) TWI615158B (pl)
WO (1) WO2014072277A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016019969A1 (en) * 2014-08-08 2016-02-11 Ludwig-Maximilians-Universität München Subcutaneously administered bispecific antibodies for use in the treatment of cancer
US9708412B2 (en) * 2015-05-21 2017-07-18 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
WO2020072306A1 (en) * 2018-10-01 2020-04-09 Amgen Inc. Methods for reducing aggregation of bispecific antibodies
CN121405815A (zh) * 2018-12-19 2026-01-27 希望之城 Baff-r双特异性t细胞衔接子抗体
TWI871300B (zh) * 2019-01-28 2025-02-01 美商安進公司 藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程
KR20220099585A (ko) * 2019-10-25 2022-07-13 암젠 인크 낮은 단백질 농도에서 단백질 손실을 최소화하기 위한 조성물 및 방법
CN115968867B (zh) * 2023-03-21 2023-07-14 天津外泌体科技有限公司 外泌体冻干保护剂和外泌体冻干制剂的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
EP1767225A1 (en) 2005-09-21 2007-03-28 Insense Limited Method for stabilisation of a protein solution by addition of hydroxyl radical quenchers and its sterilisation by ionising radiation
GB0626021D0 (en) 2006-12-29 2007-02-07 Insense Ltd The stabilisation of proteins
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
RS53008B2 (sr) 2007-04-03 2022-12-30 Amgen Res Munich Gmbh Interspecijski specifičan cd3-epsilon vezujući domen
MX2009010611A (es) 2007-04-03 2010-03-26 Micromet Ag Enlazadores biespecificos, especificos para especies.
WO2009070642A1 (en) 2007-11-28 2009-06-04 Medimmune, Llc Protein formulation
AR070316A1 (es) * 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
US7681537B2 (en) * 2008-08-17 2010-03-23 Cummins Intellectual Properties, Inc. Gas extractor for an engine coolant system
US20110293619A1 (en) * 2008-10-01 2011-12-01 Micromet Ag CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY
DK2352763T4 (da) * 2008-10-01 2022-10-17 Amgen Res Munich Gmbh Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener
JP2012530721A (ja) 2009-06-18 2012-12-06 ワイス・エルエルシー 小モジュール免疫薬のための凍結乾燥製剤
EP2501408B1 (en) 2009-11-20 2020-05-27 Biocon Limited Formulations of antibody
CN102946858B (zh) * 2010-05-10 2015-09-30 英塔斯制药有限公司 含有免疫球蛋白Fc的多肽的液体制剂
TWI719112B (zh) * 2011-03-16 2021-02-21 賽諾菲公司 雙重ｖ區類抗體蛋白質之用途
TWI815599B (zh) * 2011-04-22 2023-09-11 美商惠氏有限責任公司 與難養芽胞梭菌（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）之突變毒素有關之組成物及彼之方法

Also Published As

Publication number Publication date
CN104780940B (zh) 2017-11-07
ES2676468T3 (es) 2018-07-19
DK2916866T3 (en) 2018-07-23
CA2890166A1 (en) 2014-05-15
NZ707895A (en) 2019-07-26
TW201438764A (zh) 2014-10-16
HRP20181021T1 (hr) 2018-08-24
WO2014072277A1 (de) 2014-05-15
IL238615A0 (en) 2015-06-30
EP2916866B1 (de) 2018-04-04
HUE038151T2 (hu) 2018-10-29
AU2013343638B2 (en) 2018-08-30
CA2890166C (en) 2023-08-15
CN104780940A (zh) 2015-07-15
EP2916866A1 (de) 2015-09-16
RS57394B1 (sr) 2018-09-28
RU2679124C2 (ru) 2019-02-06
AU2018214096A1 (en) 2018-08-30
HK1211215A1 (en) 2016-05-20
US11052128B2 (en) 2021-07-06
RU2015121574A (ru) 2016-12-27
LT2916866T (lt) 2018-07-25
CY1120391T1 (el) 2019-07-10
JP6321667B2 (ja) 2018-05-09
AU2013343638A1 (en) 2015-05-28
TWI615158B (zh) 2018-02-21
TR201809507T4 (tr) 2018-07-23
MX2015005700A (es) 2015-08-20
AR093365A1 (es) 2015-06-03
SMT201800335T1 (it) 2018-09-13
SG11201502730SA (en) 2015-05-28
KR20150082328A (ko) 2015-07-15
PT2916866T (pt) 2018-07-10
MX367034B (es) 2019-08-02
JP2015536938A (ja) 2015-12-24
SI2916866T1 (en) 2018-08-31
US20150335706A1 (en) 2015-11-26

Similar Documents

Publication Publication Date Title
IL236792B (en) Engineering of t-cell receptors
EP2787722A4 (en) IMAGE FORMING DEVICE
EP2901206A4 (en) PORTABLE DEVICE
EP2904973A4 (en) RADIOGRAPHY DEVICE
TWM434649U (en) Structure for wrench clamp
AU346543S (en) Monitor mount
IL238615A0 (en) Composition for bispecific t cell integrins
EP2788559A4 (en) CABLE LOCKING DEVICE
AP3681A (en) Modified release formulations for oprozomib
GB2506432B (en) Devices for Blending Materials
EP2833614A4 (en) IMAGING DEVICE FOR WELDING
ZA201500165B (en) Device for increasing microcirculation
TWM476096U (en) Cable for bicycle
PL2712817T3 (pl) Urządzenie do opinania
GB2506398B (en) Camera apparatus
ZA201309122B (en) Photographing apparatus
PT2866993T (pt) Serra de cabo
EP2897458A4 (en) DEVICE FOR FISHING
PT2908929T (pt) Dispositivo para a mistura de produtos agrícolas
PL2692483T3 (pl) Sprzęgło do urządzenia wywołującego moment obrotowy
HU5151U (hu) Kiegészítõ eszköz
GB2494044B (en) Substance Release Device
IL219363A0 (en) Device for multi-biometrics server
IL220200A (en) Release device
GB201206310D0 (en) Camera apparatus